Anticancer activity in human multiple myeloma U266 cells: Synergy between cryptotanshinone and arsenic trioxide

Metallomics

Volumn 5, Issue 7, 2013, Pages 871-878

  Liu, Pei ^a   Xu, Shi ^b   Zhang, Min ^b,c   Wang, Wen Wen ^b,c   Zhang, Yan Fang ^b   Rehman, Kanwal ^b   Naranmandura, Hua ^b   Chen, Zhe ^a  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c CHENGDE MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICANCER ACTIVITIES; ANTICANCER EFFECTS; APOPTOTIC PATHWAYS; COMBINATION TREATMENTS; MOLECULAR MECHANISM; POLY(ADP-RIBOSE) POLYMERASE; PROMYELOCYTIC LEUKEMIA; THERAPEUTIC STRATEGY;

ARSENIC; PHOSPHORYLATION; PROTEINS;

CELL DEATH;

ARSENIC TRIOXIDE; CASPASE 3; CASPASE 9; CRYPTOTANSHINONE; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SURVIVIN; SYNAPTOPHYSIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LEUKEMIA; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; MULTIPLE MYELOMA; OXIDES; PHENANTHRENES;

EID: 84879857063     PISSN: 17565901     EISSN: 1756591X     Source Type: Journal    
DOI: 10.1039/c3mt20272k     Document Type: Article

References (29)

1. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients Blood 1997 89 3354 3360
2. V. Lallemand-Breitenbach M. Jeanne S. Benhenda R. Nasr M. Lei L. Peres J. Zhou J. Zhu B. Raught H. de Thé Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway Nat. Cell Biol. 2008 10 547 555
3. P. Bobé D. Bonardelle K. Benihoud P. Opolon M. K. Chelbi-Alix Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice Blood 2006 108 3967 3975
4. B. Ardalan P. R. Subbarayan Y. Ramos M. Gonzalez A. Fernandez D. Mezentsev I. Reis R. Duncan L. Podolsky K. Lee M. Lima P. Ganjei-Azar A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma Clin. Cancer Res. 2010 16 3019 3027
5. H. L. Kindler M. Aklilu S. Nattam E. E. Vokes Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium Am. J. Clin. Oncol. 2008 31 553 556
6. T. E. Bael B. L. Peterson J. A. Gollob Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases Melanoma Res. 2008 18 147 151
7. S. R. Kalmadi M. A. Hussein The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma Acta Haematol. 2006 116 1 7
8. S. k. Kumar S. V. Rajkumar A. Dispenzieri M. Q. Lacy S. R. Hayman F. K. Buadi S. R. Zeldenrust D. Dingli S. J. Russell J. A. Lust P. R. Greipp R. A. Kyle M. A. Gertz Improved survival in multiple myeloma and the impact of novel therapies Blood 2008 111 2516 2520
9. D. D. Alexander P. J. Mink H. O. Adami P. Cole J. S. Mandel M. M. Oken D. Trichopoulos Multiple myeloma: a review of the epidemiologic literature Int. J. Cancer 2007 12 40 61
10. C. C. Hofmeister B. Jansak N. Denlinger E. H. Kraut D. M. Benson S. S. Farag Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma Leuk. Res. 2008 32 1295 1298
11. J. R. Berenson J. Matous R. A. Swift R. Mapes B. Morrison H. S. Yeh A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma Clin. Cancer Res. 2007 13 1762 1768
12. N. C. Munshi Arsenic trioxide: an emerging therapy for multiple myeloma Oncologist 2001 2 17 21
13. T. Hayashi T. Hideshima M. Akiyama P. Richardson R. L. Schlossman D. Chauhan N. C. Munshi S. Waxman K. C. Anderson Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment Mol. Cancer Ther. 2002 1 851 860
14. C. C. Lin C. Hsu C. H. Hsu W. L. Hsu A. L. Cheng C. H. Yang Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial Invest. New Drugs 2007 25 77 84
15. K. B. Kim A. Y. Bedikian L. H. Camacho N. E. Papadopoulos C. McCullough A phase II trial of arsenic trioxide in patients with metastatic melanoma Cancer 2005 104 1687 1692
16. D. S. Shin H. N. Kim K. D. Shin Y. J. Yoon S. J. Kim D. C. Han B. M. Kwon Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells Cancer Res. 2009 69 193 202
17. W. Chen Y. Luo L. Liu H. Zhou B. Xu X. Han T. Shen Z. Liu Y. Lu S. Huang Cryptotanshinone inhibits cancer cell proliferation by suppressing mammalian target of rapamycin-mediated cyclin D1 expression and Rb phosphorylation Cancer Prev. Res. 2010 3 1015 1025
18. Y. Luo W. Chen H. Zhou L. Liu T. Shen J. S. Alexander S. Zheng Y. Lu S. Huang Cryptotanshinone inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3/ERK and small GTPase pathways Cancer Prev. Res. 2011 4 2083 2091
19. Y. Ge R. Cheng Y. Zhou J. Shen L. Peng X. Xu Q. Dai P. Liu H. Wang X. Ma J. Jia Z. Chen Cryptotanshinone induces cell cycle arrest and apoptosis of multidrug resistant human chronic myeloid leukemia cells by inhibiting the activity of eukaryotic initiation factor 4E Mol. Cell. Biochem. 2012 368 17 25
20. H. Naranmandura X. Chen M. Tanaka W. Wang K. Rehman S. Xu Z. Chen S. Chen N. Suzuki Release of apoptotic cytochrome c from mitochondria by dimethylarsinous acid occurs through interaction with voltage-dependent anion channel in vitro Toxicol. Sci. 2012 128 137 146
21. S. M. Srinivasula M. Ahmad T. Fernandes-Alnemri E. S. Alnemri Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization Mol. Cell 1998 1 949 957
22. T. Agusa T. N. Kunito N. M. Tue V. T. Lan J. Fujihara H. Takeshita T. B. Minh P. T. Trang S. Takahashi P. H. Viet S. Tanabe H. Iwata Individual variations in arsenic metabolism in Vietnamese: the association with arsenic exposure and GSTP1 genetic polymorphism Metallomics 2012 4 91 100
23. A. Arita M. Costa Epigenetics in metal carcinogenesis: nickel, arsenic, chromium and cadmium Metallomics 2009 1 222 228
24. Y. Chervona A. Arita M. Costa Carcinogenic metals and the epigenome: understanding the effect of nickel, arsenic, and chromium Metallomics 2012 4 619 627
25. S. V. Rajkumar Treatment of multiple myeloma Nat. Rev. Clin. Oncol. 2011 8 479 491
26. M. A. Hussein Trials of arsenic trioxide in multiple myeloma Cancer Control 2003 10 370 374
27. C. Röllig T. Illmer The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review Cancer Treat. Rev. 2009 35 425 430
28. P. Rousselot J. Larghero B. Arnulf J. Poupon B. Royer A. Tibi I. Madelaine-Chambrin P. Cimerman S. Chevret O. Hermine H. Dombret J. C. Brouet J. P. Fermand A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients Leukemia 2004 18 1518 1521
29. N. C. Munshi G. Tricot R. Desikan A. Badros M. Zangari A. Toor C. Morris E. Anaissie B. Barlogie Clinical activity of arsenic trioxide for the treatment of multiple myeloma Leukemia 2002 16 1835 1837